New York, June 17, 2026, 08:05 EDT
- Lunai Bioworks shares rose sharply in extended trading after the company disclosed Nasdaq had confirmed compliance with the $1 minimum bid-price rule.
- The stock was quoted at $4.65 early Wednesday, after touching $5.15 after hours on Tuesday.
- The relief is not clean-cut: Lunai remains under a one-year Nasdaq panel monitor and has warned about its need for more capital.
Lunai Bioworks Inc. shares surged in early U.S. trading on Wednesday after a company filing showed Nasdaq had confirmed the biotechnology firm was back in compliance with the exchange’s $1 minimum bid-price rule, a key threshold for keeping a listing on the market. The stock was quoted at $4.65, with reported volume of 13.48 million shares, compared with average volume of 1.98 million.
The move matters because Lunai had been fighting to stay on Nasdaq. The minimum bid price is the exchange rule that generally requires listed shares to trade at or above $1; falling below it can lead to delisting, which often hurts liquidity and access to investors. Nasdaq told the company on June 11 that it had regained compliance, according to the Form 8-K signed by Chief Executive David Weinstein and filed June 16.
The shares were the top after-hours gainer on StockAnalysis.com’s June 16 list, rising 80.88% to $5.15 after a $2.85 close. Broader index moves in the same table were muted: the S&P 500 was up 0.06%, Nasdaq 100 up 0.08%, Dow Jones up 0.09% and Russell 2000 flat in after-hours trading.
Regular Nasdaq trading had not yet opened at the time of the dateline. Nasdaq says its pre-market session runs from 4:00 a.m. to 9:30 a.m. Eastern time, with the regular session opening at 9:30 a.m.; U.S. equity markets are scheduled to close on Friday, June 19, for Juneteenth. Nasdaq
The compliance notice follows Lunai’s May reverse stock split, a step companies use to lift the per-share price by combining shares without, by itself, changing the underlying value of the business. Lunai said last month it would complete a 1-for-8 split effective May 22, cutting outstanding common shares to about 4.53 million from about 36.27 million, and said the move was intended mainly to help regain compliance with Nasdaq’s bid-price rule.
Lunai is still a very small, thinly followed name. Robinhood data put its market capitalization at $12.92 million, with a 52-week range of $1.21 to $31.04, underscoring how much volatility remains in the stock even after the compliance relief.
The company describes itself as operating through Renovaro Biosciences and BioSymetrics, with a focus on AI-driven neurology and oncology diagnostics and therapeutic development. In its latest quarterly filing, Lunai said GediCube, a unit it acquired in 2024, had filed for bankruptcy during the September 2025 quarter and ceased operations.
That places Lunai in the same investor conversation as larger AI-linked drug-discovery names such as Recursion Pharmaceuticals and Schrödinger, though at a far smaller scale. Recursion markets itself around machine learning models for AI drug discovery, while Schrödinger reported first-quarter 2026 results from both software and drug-discovery revenue streams. recursion.com
But the rally does not remove the hard parts. Nasdaq put Lunai under a mandatory one-year panel monitor, meaning another failure to meet the bid-price rule could trigger a delisting determination without a fresh grace period or compliance plan. The company also reported $3.16 million in cash, a $512.0 million accumulated deficit and a $15.55 million working-capital deficit as of March 31, and said those conditions raised substantial doubt about its ability to continue as a going concern, meaning to keep operating over the next year without enough additional funding.
For now, the trade is about listing risk. Lunai has bought time on Nasdaq, and the market has marked that as material. The next test is whether the company can keep the bid above the line and raise or conserve enough cash to fund the drug-discovery and diagnostics work behind the ticker.
